# sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial

> **NCT00533039** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 164 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Varespladib (A-002)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00533039
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2009-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533039, "sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00533039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*